Financial Performance - The company expects a net profit attributable to shareholders of between 2.3 million and 3.2 million yuan for the first half of 2024, representing a decline of 98.49% to 97.90% compared to the same period last year, where the profit was 15,212.51 million yuan[8]. - The net profit after deducting non-recurring gains and losses is projected to be between 1.8 million and 2.7 million yuan, reflecting a decrease of 98.80% to 98.21% from the previous year's profit of 15,049.53 million yuan[8]. - Basic earnings per share are expected to be between 0.005 yuan and 0.006 yuan, down from 0.336 yuan per share in the same period last year[8]. Business Transformation - The company has undergone a marketing organizational transformation, shifting from a distributor model to a hybrid model of self-operated and distributor sales[2]. Sales Performance - The sales revenue of the core product, Zhi Ke Bao Pian, has significantly declined due to reduced shipments, impacting overall performance[3]. - Despite the decrease in product shipments, the company has maintained high brand promotion expenses, leading to increased sales costs during the reporting period[3]. Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with detailed financial results to be disclosed in the 2024 semi-annual report[4].
特一药业(002728) - 2024 Q2 - 季度业绩预告